These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 9869598

  • 21. Immunohistological characterization of intraepithelial and lamina propria lymphocytes in control ileum and colon and in inflammatory bowel disease.
    Hirata I, Berrebi G, Austin LL, Keren DF, Dobbins WO.
    Dig Dis Sci; 1986 Jun; 31(6):593-603. PubMed ID: 2423309
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
    Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ.
    Gastroenterology; 1999 Oct; 117(4):761-9. PubMed ID: 10500056
    [Abstract] [Full Text] [Related]

  • 23. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group.
    Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin TH, Schering Plough (Australia).
    Intern Med J; 2001 Apr; 31(3):146-50. PubMed ID: 11478343
    [Abstract] [Full Text] [Related]

  • 24. Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-α treatment in patients with Crohn's disease.
    Dige A, Magnusson MK, Öhman L, Hvas CL, Kelsen J, Wick MJ, Agnholt J.
    Scand J Gastroenterol; 2016 Apr; 51(6):692-9. PubMed ID: 26784676
    [Abstract] [Full Text] [Related]

  • 25. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.
    ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ.
    Gut; 2002 Feb; 50(2):206-11. PubMed ID: 11788561
    [Abstract] [Full Text] [Related]

  • 26. Effect of tumor necrosis factor-α blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease.
    Biancheri P, Di Sabatino A, Rovedatti L, Giuffrida P, Calarota SA, Vetrano S, Vidali F, Pasini A, Danese S, Corazza GR, MacDonald TT.
    Inflamm Bowel Dis; 2013 Feb; 19(2):259-64. PubMed ID: 23328772
    [Abstract] [Full Text] [Related]

  • 27. Altered expression of alpha E beta 7 integrin on intra-epithelial and lamina propria lymphocytes in patients with Crohn's disease.
    Elewaut D, Van Damme N, De Keyser F, Baeten D, De Paepe P, Van Vlierberghe H, Mielants H, Cuvelier C, Verbruggen G, Veys EM, De Vos M.
    Acta Gastroenterol Belg; 1998 Feb; 61(3):288-94. PubMed ID: 9795455
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings.
    Asakura H, Yao T, Matsui T, Koganei K, Fukushima T, Takazoe M, Hobara R, Nakano H, Okamura S, Matsueda K, Kashida H, Makiyama K, Hiwatashi N, Kashiwagi K, Hibi T.
    J Gastroenterol Hepatol; 2001 Jul; 16(7):763-9. PubMed ID: 11446884
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Mechanisms in failure of infliximab for Crohn's disease.
    Nikolaus S, Raedler A, Kühbacker T, Sfikas N, Fölsch UR, Schreiber S.
    Lancet; 2000 Oct 28; 356(9240):1475-9. PubMed ID: 11081530
    [Abstract] [Full Text] [Related]

  • 32. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
    Noth R, Stüber E, Häsler R, Nikolaus S, Kühbacher T, Hampe J, Bewig B, Schreiber S, Arlt A.
    J Crohns Colitis; 2012 May 28; 6(4):464-9. PubMed ID: 22398062
    [Abstract] [Full Text] [Related]

  • 33. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease.
    Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P.
    Aliment Pharmacol Ther; 2001 Apr 28; 15(4):463-73. PubMed ID: 11284774
    [Abstract] [Full Text] [Related]

  • 34. Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice.
    Keates AC, Castagliuolo I, Cruickshank WW, Qiu B, Arseneau KO, Brazer W, Kelly CP.
    Gastroenterology; 2000 Oct 28; 119(4):972-82. PubMed ID: 11040184
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM, Perry CM.
    BioDrugs; 2002 Oct 28; 16(2):111-48. PubMed ID: 11985485
    [Abstract] [Full Text] [Related]

  • 37. Anti-interleukin-12 antibody for active Crohn's disease.
    Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W, Anti-IL-12 Crohn's Disease Study Group.
    N Engl J Med; 2004 Nov 11; 351(20):2069-79. PubMed ID: 15537905
    [Abstract] [Full Text] [Related]

  • 38. Strategies targeting tumor necrosis factor in Crohn's disease.
    Sandborn WJ.
    Acta Gastroenterol Belg; 2001 Nov 11; 64(2):170-2. PubMed ID: 11475128
    [Abstract] [Full Text] [Related]

  • 39. Stromelysin-1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn's disease patients treated with infliximab.
    Di Sabatino A, Saarialho-Kere U, Buckley MG, Gordon JN, Biancheri P, Rovedatti L, Corazza GR, Macdonald TT, Pender SL.
    Eur J Gastroenterol Hepatol; 2009 Sep 11; 21(9):1049-55. PubMed ID: 19357521
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.